Biopharma Raises $100M for Crypto Treasury to Fund Cancer Treatments

Propanc Biopharma, an Australian biotech company developing cancer treatments, has secured a substantial investment of $100 million from a crypto-focused family office. This funding will be used to establish a dedicated cryptocurrency treasury, a move described as ‘transformative’ by the company’s CEO. The proceeds will support the development of their lead product, PRP (proenzyme-based oncology platform), which aims to enter human trials in the second half of 2026. The funds will bolster the company’s balance sheet and facilitate further advancement of this innovative cancer therapy.